Effect of Colchicine vs Standard Care on Cardiac and Inflammatory Biomarkers and Clinical Outcomes in Patients Hospitalized With Coronavirus Disease 2019
Влияние колхицина по сравнению со стандартной терапией на сердечные и воспалительные биомаркеры и клинические исходы у пациентов, госпитализированных с коронавирусной инфекцией 2019 года
2020-06-24
SCID: 54.1/tat8ecdk
Discuss with AI
COVID-19cardiac biomarkerscolchicineinflammatory biomarkersrandomized clinical trial
Figures from the paper
Abstract (AI)
Importance: Severe acute respiratory syndrome coronavirus 2 infection has evolved into a global pandemic. Low-dose colchicine combines anti-inflammatory action with a favorable safety profile. Objective: To evaluate the effect of treatment with colchicine on cardiac and inflammatory biomarkers and clinical outcomes in patients hospitalized with coronavirus disease 2019 (COVID-19). Design, Setting, and Participants: In this prospective, open-label, randomized clinical trial (the Greek Study in the Effects of Colchicine in COVID-19 Complications Prevention), 105 patients hospitalized with COVID-19 were randomized in a 1:1 allocation from April 3 to April 27, 2020, to either standard medical treatment or colchicine with standard medical treatment. The study took place in 16 tertiary hospitals in Greece. Intervention: Colchicine administration (1.5-mg loading dose followed by 0.5 mg after 60 min and maintenance doses of 0.5 mg twice daily) with standard medical treatment for as long as 3 weeks. Main Outcomes and Measures: Primary end points were (1) maximum high-sensitivity cardiac troponin level; (2) time for C-reactive protein to reach more than 3 times the upper reference limit; and (3) time to deterioration by 2 points on a 7-grade clinical status scale, ranging from able to resume normal activities to death. Secondary end points were (1) the percentage of participants requiring mechanical ventilation, (2) all-cause mortality, and (3) number, type, severity, and seriousness of adverse events. The primary efficacy analysis was performed on an intention-to-treat basis. Results: A total of 105 patients were evaluated (61 [58.1%] men; median [interquartile range] age, 64 [54-76] years) with 50 (47.6%) randomized to the control group and 55 (52.4%) to the colchicine group. Median (interquartile range) peak high-sensitivity cardiac troponin values were 0.0112 (0.0043-0.0093) ng/mL in the control group and 0.008 (0.004-0.0135) ng/mL in the colchicine group (P = .34). Median (interquartile range) maximum C-reactive protein levels were 4.5 (1.4-8.9) mg/dL vs 3.1 (0.8-9.8) mg/dL (P = .73), respectively. The clinical primary end point rate was 14.0% in the control group (7 of 50 patients) and 1.8% in the colchicine group (1 of 55 patients) (odds ratio, 0.11; 95% CI, 0.01-0.96; P = .02). Mean (SD) event-free survival time was 18.6 (0.83) days the in the control group vs 20.7 (0.31) in the colchicine group (log rank P = .03). Adverse events were similar in the 2 groups, except for diarrhea, which was more frequent with colchicine group than the control group (25 patients [45.5%] vs 9 patients [18.0%]; P = .003). Conclusions and Relevance: In this randomized clinical trial, participants who received colchicine had statistically significantly improved time to clinical deterioration. There were no significant differences in high-sensitivity cardiac troponin or C-reactive protein levels. These findings should be interpreted with caution. Trial Registration: ClinicalTrials.gov Identifier: NCT04326790.
Key Findings
1
In a randomized trial of 105 hospitalized COVID-19 patients, colchicine did not significantly reduce peak high-sensitivity cardiac troponin compared with standard care (P = .34).
2
Patients received colchicine alongside standard treatment, using a 1.5-mg loading dose, an additional 0.5 mg after 60 minutes, and 0.5 mg twice daily for up to 3 weeks.
3
The abstract reports evaluation of colchicine’s effects on inflammatory response, clinical deterioration, mechanical ventilation, mortality, and adverse events in hospitalized COVID-19 patients.
4
The trial was prospective, open-label, randomized, and conducted across 16 tertiary hospitals in Greece between April 3 and April 27, 2020.
Research Object
Hospitalized patients with coronavirus disease 2019 (COVID-19)
Research Subject
The effects of low-dose colchicine, compared with standard care, on cardiac and inflammatory biomarkers, clinical deterioration, mechanical ventilation, mortality, and adverse events
Publication Details
Publication Date
2020-06-24
Journal
Publisher
ISSN
Cited by
394
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest
References available in scid.ai3
Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China2020
Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction2019
Anti-Inflammatory Treatment With Colchicine in Acute Myocardial Infarction2015